Key Takeaway: Delix Therapeutics has reported promising results from its Phase Ib trial of DLX-001, a non-hallucinogenic neuroplastogen. The trial demonstrated significant biomarker signals indicating neuroplasticity engagement and showed rapid, lasting antidepressant effects in adults suffering from major depressive disorder. This development marks a positive step forward in the treatment of MDD.
Price reaction · baseline $5.8356 (2025-11-26T15:59:00.000Z) · hit during market hours · 1 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
-1%
Market Sentiment Analysis
POSITIVE FACTORS
Strong Phase Ib trial results for DLX-001.
Demonstrated rapid and durable antidepressant effects.
Engaged neuroplasticity pathways effectively.
Full Press Release Details
Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and polysomnography) consistent with engagement of neuroplasticity pathways, while delivering rapid and durable antidepressant effects in adults with major depressive disorder (MDD).
Full Article >>
Frequently Asked Questions
What are the results of the Phase Ib trial for DLX-001?
The Phase Ib trial showed strong biomarker signals and rapid, durable antidepressant effects.
What is DLX-001 used for?
DLX-001 is a non-hallucinogenic neuroplastogen aimed at treating major depressive disorder.
What does neuroplasticity engagement mean?
Neuroplasticity engagement refers to the brain's ability to adapt and reorganize itself, which DLX-001 effectively stimulates.